Abstracts tagged "non-human primates (NHPs) and rheumatoid arthritis"

Abstract Number: 1862 • 2013 ACR/ARHP Annual Meeting
Target-Directed Development Of a Proposed Biosimilar Etanercept, GP2015: Comparability Of In Vitro Target Binding and Pre-Clinical Efficacy and Pharmacokinetics
Antonio da Silva¹, Ulrich Kronthaler¹, Cornelius Fritsch², Johann Poetzl³, Adelheid Rohde⁴, Anastassia Papandrikopoulou⁵, Hans-Peter Hofmann⁶ and Jan Marinus Visser¹, ¹Preclinical Development, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, ²Bioassay Support Global Development, Novartis Pharma AG, Basel, Switzerland, ³Bioanalytics, Sandoz Biopharmaceuticals/Hexal AG, Oberhaching, Germany, ⁴Characterisation, Sandoz Biopharmaceuticals/Hexal AG, Kundl, Austria, ⁵Medical Communications, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, ⁶Pre-clinical, Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany
Background/Purpose: Biosimilars are copy versions of existing biologic medicines that have lost patent exclusivity and are approved via stringent regulatory pathways. Biosimilars are designed to…
Abstract Number: 331 • 2012 ACR/ARHP Annual Meeting
PDL241, a Novel Humanized Monoclonal Antibody, Reveals CD319 As a Therapeutic Target for Rheumatoid Arthritis
Michel P.M. Vierboom¹, Jacky Woo², Hakju Kwon², Debra Chao², Shiming Ye², Jianmin Li², Karen Lin², Irene Tang², Nicole Belmar², Taymar Hartman², Elia Breedveld¹, Bert A. ‘t Hart¹ and Gary C. Starling², ¹Department of Immunobiology, Biomedical Primate Research Centre, Rijswijk, Netherlands, ²Abbott Biotherapeutics, Redwood City, CA
Background/Purpose: Current therapies have shown tremendous progress in the treatment of rheumatoïd arthritis (RA). However, a substantial group of RA patients are still refractory to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].